Nirmal Raj Marasine1,2, Sabina Sankhi1, Rajendra Lamichhane3. 1. Pharmaceutical Sciences Program, School of Health and Allied Sciences, Pokhara University, Pokhara-30, Kaski, Nepal. 2. Western Health Science Academy, Pokhara, Kaski, Nepal. 3. Department of Public Health, Asian College for Advance Studies, Purbanchal University, Lalitpur, Nepal.
Abstract
Aim: We aimed to evaluate the impact of pharmaceutical service intervention on medication adherence and patient-reported outcomes among patients diagnosed with depression in a private psychiatric hospital in Nepal. Methods: A single-center, open trial with a parallel design was conducted among 18 to 65 years aged patients, diagnosed with depression and under antidepressant medication(s) for ≥2 months. Patients were randomised into either the intervention or control group. The control group (n = 98) received the usual care, while the intervention group (n = 98) received a pharmaceutical service intervention. The two groups were compared using the Mann-Whitney U test, independent t-test, or chi-square test at 2 and 4 months for changes in medication adherence and patient-reported [severity of depression and health-related quality of life (HRQoL)] outcomes. Results: One hundred ninety adult patients were enrolled in the study. At baseline, there were no significant differences in any of the outcome measures between the intervention and control groups. At 2 and 4 months, the intervention group had a significant improvement only in medication adherence (P < .001) compared with the control group [MGL score: 1 (2) vs 2 (2) and 1 (1) vs 2 (1), P < .001, respectively]. Conclusion: Our study suggests that a brief pharmaceutical service intervention in the hospital setting can have a significant impact on patients' adherence to antidepressants but does not improve their severity of depression and HRQoL.
Aim: We aimed to evaluate the impact of pharmaceutical service intervention on medication adherence and patient-reported outcomes among patients diagnosed with depression in a private psychiatric hospital in Nepal. Methods: A single-center, open trial with a parallel design was conducted among 18 to 65 years aged patients, diagnosed with depression and under antidepressant medication(s) for ≥2 months. Patients were randomised into either the intervention or control group. The control group (n = 98) received the usual care, while the intervention group (n = 98) received a pharmaceutical service intervention. The two groups were compared using the Mann-Whitney U test, independent t-test, or chi-square test at 2 and 4 months for changes in medication adherence and patient-reported [severity of depression and health-related quality of life (HRQoL)] outcomes. Results: One hundred ninety adult patients were enrolled in the study. At baseline, there were no significant differences in any of the outcome measures between the intervention and control groups. At 2 and 4 months, the intervention group had a significant improvement only in medication adherence (P < .001) compared with the control group [MGL score: 1 (2) vs 2 (2) and 1 (1) vs 2 (1), P < .001, respectively]. Conclusion: Our study suggests that a brief pharmaceutical service intervention in the hospital setting can have a significant impact on patients' adherence to antidepressants but does not improve their severity of depression and HRQoL.
Authors: Maria Rubio-Valera; Marian March Pujol; Ana Fernández; M Teresa Peñarrubia-María; Pere Travé; Yolanda López Del Hoyo; Antoni Serrano-Blanco Journal: Eur Neuropsychopharmacol Date: 2012-12-06 Impact factor: 4.600
Authors: Beatriz González de León; Tasmania Del Pino-Sedeño; Pedro Serrano-Pérez; Cristobalina Rodríguez Álvarez; Daniel Bejarano-Quisoboni; María M Trujillo-Martín Journal: BMC Psychiatry Date: 2022-07-20 Impact factor: 4.144